PRINCETON, N.J., Dec. 6, 2007 (PRIME NEWSWIRE) -- Barrier Therapeutics, Inc. (Nasdaq:BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that executive management will participate in the RBC Capital Markets Healthcare Conference to be held at The Westin New York at Times Square during December 12 through December 13, 2007. Al Altomari, Chief Operating Officer of Barrier, is scheduled to participate in a panel discussion on Thursday, December 13, at 10:00 a.m. EST.
The panel discussion will be available via a live webcast and can be accessed through the Investor Relations section of Barrier Therapeutics' corporate website at: www.barriertherapeutics.com. An archive of the panel discussion will be available for replay for 30 days.
About Barrier Therapeutics
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel(r) (ketoconazole, USP) Gel, 2%, for seborrheic dermatitis; Vusion(r) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2.0%, tretinoin 0.01%) Topical Solution, for solar lentigines. Barrier Therapeutics has other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections. The company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. More information about Barrier Therapeutics can be found on its corporate website at: www.barriertherapeutics.com.
Xolegel, Vusion and Solage are trademarks of Barrier Therapeutics, Inc.